Advancing treatments for rare diseases together

Pierre Fabre and EspeRare start the EDELIFE clinical trial of a prenatal treatment for XLHED patients

16Nov

On 15th November 2021, the EspeRare Foundation and the Pierre Fabre Group announced the start of the EDELIFE clinical trial aimed at confirming the safety and efficacy of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare and debilitating congenital disease. Upon positive results, the study could lead to the first approved treatment for XLHED by 2026. The University Hospital of Erlangen in Germany is identified as the first clinical site where the study starts with Prof Schneider as the study coordinating investigator. 

"Starting patient enrolment in the EDELIFE clinical trial is a huge milestone for the Hypohidrotic Ectodermal Dysplasia community," said Caroline Kant, the Co-founder and CEO of the EspeRare Foundation, the primary sponsor of the study. According to Eric Ducournau, CEO of the Pierre Fabre Group; "The EDELIFE study truly exemplifies Pierre Fabre's commitment to supporting those with rare dermatologic diseases as we have already done in infantile hemangiomas". 

To view the press release please follow the link.